《新股消息》中國中免(601888.SH)已遞交赴港上市申請 據報集資70億至100億美元
中國中免(601888.SH)公佈,公司已於上週五(25日)向香港聯交所遞交發行上市的申請,並於同日在香港聯交所網站刊登發行上市的申請資料。
該申請資料爲公司按照香港證監會及聯交所的要求編制和刊發,爲草擬版本,其所載資料可能會適時作出更新和變動。
初步上市文件顯示,公司去年純利按年升31.9%至59.3億元人民幣,營業收入按年增9.6%至526億元人民幣。此次上市集資所得用於拓展海外渠道、鞏固內地渠道、促進產業鏈延伸、提升效率等。
據路透旗下《IFR》日前報道,中國中免將最快於下個星期內向聯交所提交上市申請,目標集資約70億至100億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.